Product logins

Find logins to all Clarivate products below.


Olaparib

LYNPARZA®

About LYNPARZA®

  • Marketed by AstraZeneca
  • Poly ADP ribose polymerase (PARP) inhibitor
  • Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, metastatic breast, metastatic pancreatic or primary peritoneal cancer who have had complete or partial response to platinum-based chemotherapy

Review and approval status

December 16, 2014

First U.S. approval date

December 19, 2014

First E.U. approval date

Constraint date forecast:

  • Orphan Drug Exclusivity expiry: 2024 (United States)
  • SPC expiries: 2029 (European Union)
  • Patent expiries: 2024 (Japan)

Drug Timeline & Success Rates